SEMAGLUTIDE MEDICAL WEIGHT LOSS
Age Management of West Michigan
Conventional, Functional, and Anti-Aging Regenerative Medicine located in Grand Rapids MI.
Dr. Shahnaz Ali Dr. Piyush Bhatnagar
The Semaglutide Medical Weight Loss Program utilizes Semaglutide GLP-1 injections along with a 16 week nutrition program to promote successful long term weight loss. Semaglutide is the newest FDA approved medication available for weight loss. Semaglutide promotes a decrease in appetite to support a low calorie diet and stabilizes insulin levels to keep the body in a fat burning state. Age Management of West Michigan's Semaglutide Medical Weight Loss Program is unique by providing a structured program of nutrition, exercise, biometric screening, Vitamin B12 injections, and behavioral modification techniques along with bi-weekly nutritionist consultations for guidance to build healthy habits for long term success.
Semaglutide Medical Weight Loss Program
16 Week Program
Weeks 1-4: 0.25mg Injection
Weeks 5-8: 0.5mg Injection
Weeks 8-12: 1.0mg Injection
Weeks 13-16: 1.7mg Injection
Dosing Schedule: One Injection Weekly
Weeks 17+: 2.4mg Injection
16 Week Program Includes:
Bi-weekly Nutritionist Consultation
Nutrition and Exercise Program
Bi-Weekly B-12 Injections
BIA Composition Measurements
Participant's must have BMI > 27 to be eligible to participate. Physician appointment for prescreening and program participation approval required. Semaglutide program participants are required to attend bi-weekly consultations for monitoring and support. Semaglutide injections are dispersed to patient at bi-weekly appointments and self-administered at home. Patients unable to attend bi-weekly appointments must get pre-approval to do virtual or phone consultations instead of in person visits. All participants are required to do a physician follow up at week 8 and 16 of the program. After the initial 16 week program, participants are not required to attend bi-weekly consultations to purchase monthly semaglutide injections (2.4mg long term dosing).